<?xml version="1.0"?>
<template xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="openEHR/v1/Template">
  <id>635bc8b3-6d64-449c-92b6-0bd33cd5dc69</id>
  <name>Hypophysitis Checkpoint Inhibitor Related Toxicity Medications Adult</name>
  <description>
    <lifecycle_state>Initial</lifecycle_state>
    <details>
      <purpose/>
      <use/>
      <misuse/>
    </details>
    <other_details>
      <item>
        <key>MetaDataSet:Sample Set </key>
        <value>Template metadata sample set </value>
      </item>
      <item>
        <key>Acknowledgements</key>
        <value/>
      </item>
      <item>
        <key>Business Process Level</key>
        <value/>
      </item>
      <item>
        <key>Care setting</key>
        <value/>
      </item>
      <item>
        <key>Client group</key>
        <value/>
      </item>
      <item>
        <key>Clinical Record Element</key>
        <value/>
      </item>
      <item>
        <key>Copyright</key>
        <value/>
      </item>
      <item>
        <key>Issues</key>
        <value/>
      </item>
      <item>
        <key>Owner</key>
        <value/>
      </item>
      <item>
        <key>Sign off</key>
        <value/>
      </item>
      <item>
        <key>Speciality</key>
        <value/>
      </item>
      <item>
        <key>User roles</key>
        <value/>
      </item>
    </other_details>
  </description>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.clinical_guidance.v1]">
    <items>
      <item>
        <key>CKT.Clinical Guidance</key>
        <value>&lt;table border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Grading&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Management&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;G1: Asymptomatic or mild symptoms&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Consider holding ICPi until patient is stabilized on replacement hormones&lt;/p&gt;&lt;p&gt;- Hormonal supplementation as needed, using dosing as above for primary hypothyroidism and adrenal insufficiency (eg, hydrocortisone 10-20 mg orally in the morning, 5-10 mg orally in early afternoon; levothyroxine by weight&lt;/p&gt;&lt;p&gt;- Testosterone or estrogen therapy as needed in those without contraindications&lt;/p&gt;&lt;p&gt;- Endocrine consultation&lt;/p&gt;&lt;p&gt;-&amp;nbsp;Always start corticosteroids several days before thyroid hormone to prevent precipitating adrenal crisis&lt;/p&gt;&lt;p&gt;-&amp;nbsp;Follow FT4 for thyroid hormone replacement titration (TSH is not accurate)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;G2: Moderate symptoms, able to perform ADL&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Consider holding ICPi until patient is stabilized on replacement hormones&lt;/p&gt;&lt;p&gt;-&amp;nbsp;Endocrine consultation&lt;/p&gt;&lt;p&gt;-&amp;nbsp;Hormonal supplementation as in G1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;G3-4: Severe symptoms, medically significant or life-threatening consequences, unable to perform ADL&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Hold ICPi until patient is stabilized on replacement hormones&lt;/p&gt;&lt;p&gt;-&amp;nbsp;Endocrine consultation&lt;/p&gt;&lt;p&gt;-&amp;nbsp;Hormonal supplementation as in G1&lt;/p&gt;&lt;p&gt;- Consider initial pulse dose therapy with prednisone 1-2 mg/kg oral daily (or equivalent) tapered over at least 1-2 weeks&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Additional considerations&lt;/p&gt;&lt;p&gt;-&amp;nbsp;Be aware of the need to start corticosteroids first when planning hormone replacement therapy for multiple deficiencies&lt;/p&gt;&lt;p&gt;- All patients need instruction on doubling doses for illness (stress dosing) and a medical alert bracelet for adrenal insufficiency to trigger stress-dose corticosteroids by EMS&lt;/p&gt;&lt;p&gt;-&amp;nbsp;Corticosteroid use can cause isolated central adrenal insufficiency&lt;/p&gt;&lt;p&gt;-&amp;nbsp;Work-up cannot be done with a simple AM cortisol in a patient on corticosteroids for other conditions&lt;/p&gt;&lt;p&gt;-&amp;nbsp;Laboratory confirmation of adrenal insufficiency should not be attempted until treatment with corticosteroids for other disease is ready to be discontinued&lt;/p&gt;&lt;p&gt;- For long-term exposure, consult endocrinology for recovery and waning protocol using hydrocortisone&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]"><items><item><key>Technical.ï»© Technical Traceability</key><value>{~AHSID~635bc8b3-6d64-449c-92b6-0bd33cd5dc69~NAME~Hypophysitis Checkpoint Inhibitor Related Toxicity Medications Adult}</value></item></items></annotations><definition xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" name="Hypophysitis Toxicity Medications">
    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="Clinical Decision Support"/>
  </definition>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.adhoc.v1">
    <digest id="MD5-CAM-1.0.1">8AE70853975A75254E6D39A8DE3652AF</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1">
    <digest id="MD5-CAM-1.0.1">4B2F0F6CD593E442DA9C30277A3EA9CF</digest>
  </integrity_checks>
</template>